Selected references

  1. Aubry-Rozier B. [Role of slow-acting anti-arthritic agents in osteoarthritis (chondroitin sulfate, glucosamine, hyaluronic acid)]. Rev.Med.Suisse 3-14-2012;8(332):571-2, 574, 576.
  2. Chen WC, Yao CL, Chu IM, et al. Compare the effects of chondrogenesis by culture of human mesenchymal stem cells with various type of the chondroitin sulfate C. J.Biosci.Bioeng. 2011;111(2):226-231.
  3. Coppa GV, Gabrielli O, Buzzega D, et al. Composition and structure elucidation of human milk glycosaminoglycans. Glycobiology 2011;21(3):295-303.
  4. De Vita D and Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int.Urogynecol.J. 2012;23(12):1707-1713.
  5. Furer V, Wieczorek RL, and Pillinger MH. Bilateral pinna chondritis preceded by glucosamine chondroitin supplement initiation. Scand.J.Rheumatol. 2011;40(3):241-243.
  6. Gabay C, Medinger-Sadowski C, Gascon D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum. 2011;63(11):3383-3391.
  7. Kanzaki N, Saito K, Maeda A, et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled study. J.Sci.Food Agric. 3-15-2012;92(4):862-869.
  8. Luhn S, Schiemann S, and Alban S. Simple fluorescence assay for quantification of OSCS in heparin. Anal.Bioanal.Chem. 2011;399(2):673-680.
  9. Martin M, Ott H, Merk HF, et al. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins. Br.J.Dermatol. 2011;164(1):68-75.
  10. Nickel JC, Hanno P, Kumar K, et al. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology 2012;79(6):1220-1224.
  11. Railhac JJ, Zaim M, Saurel AS, et al. Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI. Clin.Rheumatol. 2012;31(9):1347-1357.
  12. Tsui T, Boon H, Boecker A, et al. Understanding the role of scientific evidence in consumer evaluation of natural health products for osteoarthritis an application of the means end chain approach. BMC.Complement Altern.Med. 2012;12:198.
  13. Van Vijven JP, Luijsterburg PA, Verhagen AP, et al. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review. Osteoarthritis.Cartilage. 2012;20(8):809-821.
  14. Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann.Rheum.Dis. 2011;70(6):982-989.
  15. Yue J, Yang M, Yi S, et al. Chondroitin sulfate and/or glucosamine hydrochloride for Kashin-Beck disease: a cluster-randomized, placebo-controlled study. Osteoarthritis.Cartilage. 2012;20(7):622-629.

This evidence-based monograph was prepared by The Natural Standard Research Collaboration